新型口服头孢菌素BMY - 28100的体外活性
In vitro activity of BMY-28100, a new oral cephalosporin.
作者信息
Eliopoulos G M, Reiszner E, Wennersten C, Moellering R C
出版信息
Antimicrob Agents Chemother. 1987 Apr;31(4):653-6. doi: 10.1128/AAC.31.4.653.
Abstract
The activity of BMY-28100, a new orally administered cephalosporin, was compared with those of cephalexin and cefaclor. BMY-28100 was the most active drug against Staphylococcus aureus (MIC for 90% of strains tested [MIC90], 1.0 microgram/ml), streptococci (MIC90S, less than or equal to 0.125 microgram/ml), and Klebsiella pneumoniae (MIC90, 2 micrograms/ml). The drug was active against Haemophilus influenzae and gonococci but not against other organisms generally resistant to cephem antibiotics.
摘要
将新型口服头孢菌素BMY - 28100的活性与头孢氨苄和头孢克洛进行了比较。BMY - 28100对金黄色葡萄球菌（90%受试菌株的最低抑菌浓度[MIC90]为1.0微克/毫升）、链球菌（MIC90S≤0.125微克/毫升）和肺炎克雷伯菌（MIC90为2微克/毫升）是活性最强的药物。该药物对流感嗜血杆菌和淋球菌有活性，但对其他通常对头孢烯类抗生素耐药的微生物无活性。
相似文献
1
In vitro activity of BMY-28100, a new oral cephalosporin.新型口服头孢菌素BMY - 28100的体外活性
Antimicrob Agents Chemother. 1987 Apr;31(4):653-6. doi: 10.1128/AAC.31.4.653.
2
In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin.新型口服头孢菌素BMY-28100的体外和体内评价
J Antibiot (Tokyo). 1987 Aug;40(8):1175-83. doi: 10.7164/antibiotics.40.1175.
3
BMY 28100, a new oral cephalosporin.BMY 28100，一种新型口服头孢菌素。
Antimicrob Agents Chemother. 1987 Feb;31(2):238-43. doi: 10.1128/AAC.31.2.238.
4
BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.新型口服头孢菌素BMY-28100：对近7000株近期临床分离菌株的抗菌活性、与其他口服制剂的相对效价以及对产β-内酰胺酶分离菌株的活性
Diagn Microbiol Infect Dis. 1988 Jan;9(1):11-26. doi: 10.1016/0732-8893(88)90056-9.
5
In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.口服亚胺甲氧基氨噻唑基头孢菌素R-3746的体外活性
Antimicrob Agents Chemother. 1988 May;32(5):671-7. doi: 10.1128/AAC.32.5.671.
6
In vitro studies with Bay V 3522, a new oral cephalosporin.使用新型口服头孢菌素Bay V 3522进行的体外研究。
Drugs Exp Clin Res. 1991;17(3):165-73.
7
The in-vitro activity of cefdinir (FK482), a new oral cephalosporin.新型口服头孢菌素头孢地尼（FK482）的体外活性
J Antimicrob Chemother. 1991 Aug;28(2):239-48. doi: 10.1093/jac/28.2.239.
8
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.新型口服活性头孢菌素FR 17027的体外活性及β-内酰胺酶稳定性比较
Antimicrob Agents Chemother. 1984 Aug;26(2):174-80. doi: 10.1128/AAC.26.2.174.
9
Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.新型口服头孢菌素BMY-28100的抗菌活性比较
Antimicrob Agents Chemother. 1987 Mar;31(3):480-3. doi: 10.1128/AAC.31.3.480.
10
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.新型广谱头孢菌素BMY-28142的体外活性评估
Antimicrob Agents Chemother. 1985 May;27(5):679-82. doi: 10.1128/AAC.27.5.679.
引用本文的文献
1
Redefining the management of pediatric tonsillopharyngitis with cefprozil.用头孢丙烯重新定义小儿扁桃体咽炎的治疗。
Indian J Pediatr. 2007 Dec;74(12):1105-8. doi: 10.1007/s12098-007-0206-8.
2
Penetration of cefprozil into tonsillar and adenoidal tissues.头孢丙烯在扁桃体和腺样体组织中的渗透情况。
Antimicrob Agents Chemother. 1993 May;37(5):1180-3. doi: 10.1128/AAC.37.5.1180.
3
Effects of time of administration and posture on the pharmacokinetics of cefprozil.给药时间和体位对头孢丙烯药代动力学的影响。
Clin Pharmacokinet. 1993 Sep;25(3):237-42. doi: 10.2165/00003088-199325030-00006.
4
Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis.头孢丙烯与青霉素V治疗链球菌性扁桃体咽炎的对比
Antimicrob Agents Chemother. 1993 Aug;37(8):1620-3. doi: 10.1128/AAC.37.8.1620.
5
Penetration of cefprozil into middle ear fluid of patients with otitis media.头孢丙烯在中耳炎患者中耳液中的渗透情况。
Antimicrob Agents Chemother. 1994 Sep;38(9):2210-2. doi: 10.1128/AAC.38.9.2210.
6
Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.头孢丙烯。对其抗菌活性、药代动力学特性及治疗潜力的综述。
Drugs. 1993 Feb;45(2):295-317. doi: 10.2165/00003495-199345020-00008.
7
Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.新型口服头孢菌素BMY-28100的纸片扩散药敏试验及肉汤微量稀释法质量控制指南
J Clin Microbiol. 1987 Nov;25(11):2211-3. doi: 10.1128/jcm.25.11.2211-2213.1987.
8
Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor.食物对头孢丙烯和头孢克洛药代动力学影响的比较。
Antimicrob Agents Chemother. 1990 Jun;34(6):1210-3. doi: 10.1128/AAC.34.6.1210.
9
Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.头孢丙烯与头孢克洛的药代动力学及组织穿透性比较。
Antimicrob Agents Chemother. 1990 Jun;34(6):1204-9. doi: 10.1128/AAC.34.6.1204.
10
Phase I study of multiple-dose cefprozil and comparison with cefaclor.多剂量头孢丙烯的I期研究及其与头孢克洛的比较。
Antimicrob Agents Chemother. 1990 Jun;34(6):1198-203. doi: 10.1128/AAC.34.6.1198.
本文引用的文献
1
Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms.类白喉杆菌人工瓣膜心内膜炎。临床特征与感染微生物的研究。
Am J Med. 1980 Dec;69(6):838-48. doi: 10.1016/s0002-9343(80)80009-x.
2
In-vitro activity of Sch 29482 in comparison with other oral antibiotics.Sch 29482与其他口服抗生素相比的体外活性。
J Antimicrob Chemother. 1982 Feb;9 Suppl C:143-52. doi: 10.1093/jac/9.suppl_c.143.
3
Effect of protein binding on the activity of penicillins in combination with gentamicin against enterococci.蛋白质结合对青霉素与庆大霉素联合抗肠球菌活性的影响。
Antimicrob Agents Chemother. 1979 Jan;15(1):87-92. doi: 10.1128/AAC.15.1.87.
Zotero 插件